Every Form 4 that Dexcom Inc (DXCM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DXCM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DXCM filings page.
DXCM executive vice president and chief financial officer Jereme M. Sylvain reported equity award activity in company common stock. On January 29, 2026, he acquired 7,123 shares at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were achieved.
On the same date, 2,652 shares were withheld at $73.36 per share to satisfy tax obligations related to this vesting, which the footnotes clarify was not a sale. After these transactions, he directly beneficially owned 123,207 shares, including 83,328 unvested restricted stock units scheduled to vest between March 8, 2026 and March 8, 2028 and 79 shares acquired under the company’s employee stock purchase plan.
DexCom executive Michael Jon Brown, EVP and Chief Legal Officer, reported routine equity activity on January 29, 2026. He received 7,123 shares of common stock at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were met.
To cover tax withholding on this PSU settlement, 2,653 shares were withheld by the issuer at $73.36 per share, which the filing states does not represent a sale by Brown. After these transactions, he directly owned 98,655 shares, including 86,490 unvested restricted stock units with various vesting schedules through March 8, 2028 and 83 shares acquired under the company’s employee stock purchase plan.
Dexcom Executive Chair Kevin R. Sayer reported equity compensation activity involving the company’s common stock. On January 29, 2026, he received 71,218 shares at $0 upon vesting of performance-based restricted stock units granted on March 9, 2023, after performance conditions were achieved.
On the same date, 34,257 shares at $73.36 were withheld by Dexcom to cover tax obligations related to this PSU settlement, which the filing states does not represent a sale by Sayer. Following these transactions, he directly beneficially owns 408,990 shares of Dexcom common stock.
Included in this amount are 138,091 unvested restricted stock units, consisting of 85,490 RSUs granted on March 8, 2025 that vest through March 8, 2028, 34,461 RSUs granted on March 8, 2024 that vest through March 8, 2027, and 18,140 RSUs granted on March 9, 2023 that vest through March 8, 2026.
DexCom, Inc. director trade: A DexCom (DXCM) director reported selling 2,906 shares of common stock on 11/14/2025 at $59.05 per share. The transaction was executed by the Richard A. Collins Revocable Trust under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, designed to allow orderly sales over time. Following this sale, the trust holds 35,088 DexCom shares indirectly for the reporting person, and the director also holds 5,074 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of one year from grant or DexCom’s 2026 annual meeting of stockholders.
DexCom (DXCM) director Bridgette P. Heller reported an open-market sale of 1,012 common shares at $58.07 on November 12, 2025, executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
Following the transaction, she beneficially owns 27,031 shares directly, which include 5,046 unvested RSUs granted May 8, 2025 that vest on the earlier of the one-year anniversary or DexCom’s 2026 annual meeting.
DexCom (DXCM) reported insider purchases by its President & COO, Jacob Steven Leach. On 11/10/2025, he bought 15,700 shares at a weighted average price of $54.977 and 2,500 shares at a weighted average price of $55.4252, executed in multiple trades within disclosed price ranges.
Following these transactions, he directly beneficially owned 331,697 shares. That total includes 84,537 unvested restricted stock units scheduled to vest through March 2026–2028 as previously granted. In addition, 47,296 shares are indirectly held through the Gregg Family Grandchildren's Trust, for which his spouse serves as a trustee.
Dexcom (DXCM) insider activity: Director Richard A. Collins, through the Richard A. Collins Revocable Trust, sold 3,948 shares of common stock on 11/10/2025 at $55.17 per share, pursuant to a Rule 10b5-1 plan adopted on August 7, 2025.
Following the sale, 37,994 shares are beneficially owned indirectly by the Trust. In addition, 5,074 unvested RSUs granted on May 8, 2025 will vest on the earlier of the one-year grant anniversary or DexCom’s 2026 Annual Meeting of Stockholders.
Dexcom, Inc. (DXCM) reported that director Euan Ashley acquired 7,166 restricted stock units on 10/24/2025 via a Form 4 filing.
The RSU grant was recorded at a $0 price and is scheduled to vest in three equal annual installments from the grant date. Following this transaction, the reporting person beneficially owned 7,166 shares, held with direct ownership.